Celgene: Is The Bottom In?

After the first quarter earnings report and revised guidance the stock of this biotech stalward seems to have bottomed.

Curiosity is only vanity. We usually only want to know something so that we can talk about it. ― Blaise Pascal

It has been a challenging six months for shareholders of biotech stalwart Celgene (CELG). The stock as can be seen below has been a poor performer in the overall market. The company and its shares have been hit by a series of trial disappointments and worries about whether a major pipeline asset will see eventual FDA approval.

Comments

Stories